Pharmacopsychiatry 2020; 53(04): 179-183
DOI: 10.1055/a-0914-3234
Original Paper

Roadmap for Routine Pharmacogenetic Testing in a Psychiatric University Hospital

Andreas Menke
1   Department of Psychiatry, Psychosomatics and Psychotherapy, Center of Mental Health, University Hospital of Würzburg, Würzburg, Germany
,
Heike Weber
1   Department of Psychiatry, Psychosomatics and Psychotherapy, Center of Mental Health, University Hospital of Würzburg, Würzburg, Germany
,
Jürgen Deckert
1   Department of Psychiatry, Psychosomatics and Psychotherapy, Center of Mental Health, University Hospital of Würzburg, Würzburg, Germany
› Author Affiliations

Abstract

Major depressive disorder (MDD) implicates a huge burden for patients and society. Although currently available antidepressants are effective treatment options, more than 50% of the patients do not respond to the first administered antidepressant. In addition, in more than 25% with antidepressants-treated patients, adverse effects occur. Currently, the selection of treatment does not reflect objectively measurable data from neurobiological and behavioral systems. However, in the last decades, the understanding of the impact of genetic variants on clinical features such as drug metabolism has grown and can be used to develop tests that enable a patient-tailored individual treatment. In fact, robust evidence was found that genetic variants of CYP450 enzymes such as CYP2D6 and CYP2C19 can be surrogate markers for the metabolism of certain drugs. This article describes a pilot study design aimed to combine clinical variables such as therapeutic drug monitoring, inflammatory and stress markers with static and variable genetic information of depressed patients to develop an algorithm that predicts treatment response, and tolerability using machine learning algorithms. Psychometric evaluation covers the Hamilton Depression Rating Scale, the Childhood Trauma Questionnaire, and adverse drug reactions. An in-depth (epi-)genetic assessment combines genome-wide gene association data with DNA methylation patterns of genes coding CYP enzymes along with a pharmacogenetic battery focusing on CYP enzymes. Using these measures to stratify depressed patients, this approach should contribute to a data-driven assessment and management of MDD, which can be referred to as precision medicine or high-definition medicine.



Publication History

Received: 14 January 2019
Received: 29 March 2019

Accepted: 29 April 2019

Article published online:
11 June 2019

© Georg Thieme Verlag KG
Stuttgart · New York

 
  • References

  • 1 Wittchen HU, Jacobi F, Rehm J. et al. The size and burden of mental disorders and other disorders of the brain in Europe 2010. Eur Neuropsychopharmacol 2011; 21: 655-679
  • 2 Otte C, Gold SM, Penninx BW. et al. Major depressive disorder. Nat Rev Dis Primers 2016; 2: 16065
  • 3 Ruhe HG, Huyser J, Swinkels JA. et al. Switching antidepressants after a first selective serotonin reuptake inhibitor in major depressive disorder: a systematic review. J Clin Psychiatry 2006; 67: 1836-1855
  • 4 Rush AJ, Trivedi MH, Wisniewski SR. et al. Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N Engl J Med 2006; 354: 1231-1242
  • 5 Ormel J, Oldehinkel AJ, Nolen WA. et al. Psychosocial disability before, during, and after a major depressive episode: a 3-wave population-based study of state, scar, and trait effects. Arch Gen Psychiatry 2004; 61: 387-392
  • 6 Mishra S, Swain TR, Mohanty M. Adverse drug reaction monitoring of antidepressants in the psychiatry outpatients department of a tertiary care teaching hospital. J Clin Diagn Res 2013; 7: 1131-1134
  • 7 Perlis RH. Abandoning personalization to get to precision in the pharmacotherapy of depression. World Psychiatry 2016; 15: 228-235
  • 8 Menke A. Precision pharmacotherapy: psychiatry’s future direction in preventing, diagnosing, and treating mental disorders. Pharmgenomics Pers Med 2018; 11: 211-222
  • 9 Collins FS, Varmus H. A new initiative on precision medicine. N Engl J Med 2015; 372: 793-795
  • 10 Jameson JL, Longo DL. Precision medicine–personalized, problematic, and promising. N Engl J Med 2015; 372: 2229-2234
  • 11 Holsboer F. How can we realize the promise of personalized antidepressant medicines?. Nat Rev Neurosci 2008; 9: 638-646
  • 12 Sullivan PF, Neale MC, Kendler KS. Genetic epidemiology of major depression: review and meta-analysis. Am J Psychiatry 2000; 157: 1552-1562
  • 13 Tansey KE, Guipponi M, Hu X. et al. Contribution of common genetic variants to antidepressant response. Biol Psychiatry 2013; 73: 679-682
  • 14 Uher R, Perroud N, Ng MY. et al. Genome-wide pharmacogenetics of antidepressant response in the GENDEP project. Am J Psychiatry 2010; 167: 555-564
  • 15 Ising M, Lucae S, Binder EB. et al. A genomewide association study points to multiple loci that predict antidepressant drug treatment outcome in depression. Arch Gen Psychiatry 2009; 66: 966-975
  • 16 Garriock HA, Kraft JB, Shyn SI. et al. A genomewide association study of citalopram response in major depressive disorder. Biol Psychiatry 2010; 67: 133-138
  • 17 GENDEP Investigators, MARS Investigators, STAR*D Investigators. Common genetic variation and antidepressant efficacy in major depressive disorder: a meta-analysis of three genome-wide pharmacogenetic studies. Am J Psychiatry 2013; 170: 207-217
  • 18 Zeier Z, Carpenter LL, Kalin NH. et al. Clinical implementation of pharmacogenetic decision support tools for antidepressant drug prescribing. Am J Psychiatry 2018; 175: 873-886
  • 19 Niitsu T, Fabbri C, Bentini F. et al. Pharmacogenetics in major depression: a comprehensive meta-analysis. Prog Neuropsychopharmacol Biol Psychiatry 2013; 45: 183-194
  • 20 McMahon FJ. Clinically useful genetic markers of antidepressant response: how do we get there from here?. Am J Psychiatry 2015; 172: 697-699
  • 21 Nassan M, Nicholson WT, Elliott MA. et al. Pharmacokinetic pharmacogenetic prescribing guidelines for antidepressants: a template for psychiatric precision medicine. Mayo Clin Proc 2016; 91: 897-907
  • 22 Muller DJ, Kekin I, Kao AC. et al. Towards the implementation of CYP2D6 and CYP2C19 genotypes in clinical practice: update and report from a pharmacogenetic service clinic. Int Rev Psychiatry 2013; 25: 554-571
  • 23 Rosenblat JD, Lee Y, McIntyre RS. Does pharmacogenomic testing improve clinical outcomes for major depressive disorder? A systematic review of clinical trials and cost-effectiveness studies. J Clin Psychiatry 2017; 78: 720-729
  • 24 Hicks JK, Sangkuhl K, Swen JJ. et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther 2017; 102: 37-44
  • 25 Bousman C, Maruf AA, Muller DJ. Towards the integration of pharmacogenetics in psychiatry: a minimum, evidence-based genetic testing panel. Curr Opin Psychiatry 2019; 32: 7-15
  • 26 U.S. Food and Drug Administration. Table of Pharmacogenomic Biomarkers in Drug Labeling. 2019; Available at https://www.fda.gov/Drugs/ScienceResearch/ucm572698.htm
  • 27 Fabbri C, Hosak L, Mossner R. et al. Consensus paper of the WFSBP Task Force on Genetics: genetics, epigenetics and gene expression markers of major depressive disorder and antidepressant response. World J Biol Psychiatry 2017; 18: 5-28
  • 28 Bousman CA, Forbes M, Jayaram M. et al. Antidepressant prescribing in the precision medicine era: a prescriber’s primer on pharmacogenetic tools. BMC Psychiatry 2017; 17: 60
  • 29 Bousman CA, Hopwood M. Commercial pharmacogenetic-based decision-support tools in psychiatry. Lancet Psychiatry 2016; 3: 585-590
  • 30 Bousman CA, Arandjelovic K, Mancuso SG. et al. Pharmacogenetic tests and depressive symptom remission: a meta-analysis of randomized controlled trials. Pharmacogenomics 2019; 20: 37-47
  • 31 Bschor T, Baethge C, Hiemke C. et al. [Genetic tests for controlling treatment with antidepressants]. Nervenarzt 2017; 88: 495-499
  • 32 Rosenblat JD, Lee Y, McIntyre RS. The effect of pharmacogenomic testing on response and remission rates in the acute treatment of major depressive disorder: a meta-analysis. J Affect Disord 2018; 241: 484-491
  • 33 Fabbri C, Kasper S, Kautzky A. et al. Genome-wide association study of treatment-resistance in depression and meta-analysis of three independent samples. Br J Psychiatry 2019; 214: 36-41
  • 34 Fabbri C, Zohar J, Serretti A. Pharmacogenetic tests to guide drug treatment in depression: comparison of the available testing kits and clinical trials. Prog Neuropsychopharmacol Biol Psychiatry 2018; 86: 36-44
  • 35 Kaptchuk TJ, Miller FG. Placebo Effects in Medicine. N Engl J Med 2015; 373: 8-9
  • 36 Finniss DG, Kaptchuk TJ, Miller F. et al. Biological, clinical, and ethical advances of placebo effects. Lancet 2010; 375: 686-695
  • 37 Colloca L, Finniss D. Nocebo effects, patient-clinician communication, and therapeutic outcomes. JAMA 2012; 307: 567-568
  • 38 Crum AJ, Leibowitz KA, Verghese A. Making mindset matter. BMJ 2017; 356: j674
  • 39 Turnwald BP, Goyer JP, Boles DZ. et al. Learning one’s genetic risk changes physiology independent of actual genetic risk. Nat Hum Behav 2019; 3: 48-56
  • 40 Menke A, Lehrieder D, Fietz J. et al. Childhood trauma dependent anxious depression sensitizes HPA axis function. Psychoneuroendocrinology 2018; 98: 22-29
  • 41 Danese A, Lewis SJ. Psychoneuroimmunology of early-life stress: the hidden wounds of childhood trauma?. Neuropsychopharmacology 2017; 42: 99-114
  • 42 Hauser W, Schmutzer G, Brahler E. et al. Maltreatment in childhood and adolescence: results from a survey of a representative sample of the German population. Dtsch Arztebl Int 2011; 108: 287-294
  • 43 Hiemke C, Bergemann N, Clement HW. et al. Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017. Pharmacopsychiatry 2018; 51: 9-62
  • 44 Kohler O, Benros ME, Nordentoft M. et al. Effect of anti-inflammatory treatment on depression, depressive symptoms, and adverse effects: a systematic review and meta-analysis of randomized clinical trials. JAMA Psychiatry 2014; 71: 1381-1391
  • 45 Kappelmann N, Lewis G, Dantzer R. et al. Antidepressant activity of anti-cytokine treatment: a systematic review and meta-analysis of clinical trials of chronic inflammatory conditions. Mol Psychiatry 2018; 23: 335-343
  • 46 Dantzer R, O’Connor JC, Freund GG. et al. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci 2008; 9: 46-56
  • 47 Miller AH, Raison CL. The role of inflammation in depression: from evolutionary imperative to modern treatment target. Nat Rev Immunol 2016; 16: 22-34
  • 48 Holsboer F. The corticosteroid receptor hypothesis of depression. Neuropsychopharmacology 2000; 23: 477-501
  • 49 Pariante CM, Miller AH. Glucocorticoid receptors in major depression: relevance to pathophysiology and treatment. Biol Psychiatry 2001; 49: 391-404
  • 50 Schatzberg AF. Anna-Monika Award Lecture, DGPPN Kongress, 2013: the role of the hypothalamic-pituitary-adrenal (HPA) axis in the pathogenesis of psychotic major depression. World J Biol Psychiatry 2015; 16: 2-11
  • 51 Soria V, Gonzalez-Rodriguez A, Huerta-Ramos E. et al. Targeting hypothalamic-pituitary-adrenal axis hormones and sex steroids for improving cognition in major mood disorders and schizophrenia: a systematic review and narrative synthesis. Psychoneuroendocrinology 2018; 93: 8-19
  • 52 Dunlop BW, Binder EB, Iosifescu D. et al. Corticotropin-releasing factor receptor 1 antagonism is ineffective for women with posttraumatic stress disorder. Biol Psychiatry 2017; 82: 866-874
  • 53 Zobel AW, Nickel T, Kunzel HE. et al. Effects of the high-affinity corticotropin-releasing hormone receptor 1 antagonist R121919 in major depression: the first 20 patients treated. J Psychiatr Res 2000; 34: 171-181
  • 54 Leistner C, Menke A. How to measure glucocorticoid receptor’s sensitivity in patients with stress-related psychiatric disorders. Psychoneuroendocrinology 2018; 91: 235-260
  • 55 Tang X, Chen S. Epigenetic regulation of cytochrome P450 enzymes and clinical implication. Curr Drug Metab 2015; 16: 86-96
  • 56 Hirota T, Takane H, Higuchi S. et al. Epigenetic regulation of genes encoding drug-metabolizing enzymes and transporters; DNA methylation and other mechanisms. Curr Drug Metab 2008; 9: 34-38
  • 57 McMahon FJ. Prediction of treatment outcomes in psychiatry–where do we stand?. Dialogues Clin Neurosci 2014; 16: 455-464
  • 58 Kessler RC, van Loo HM, Wardenaar KJ. et al. Testing a machine-learning algorithm to predict the persistence and severity of major depressive disorder from baseline self-reports. Mol Psychiatry 2016; 21: 1366-1371
  • 59 Lin E, Kuo PH, Liu YL. et al. A deep learning approach for predicting antidepressant response in major depression using clinical and genetic biomarkers. Front Psychiatry 2018; 9: 290